Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.
Lexicon is the only company to have systematically studied the role and function of thousands of genes, identifying more than 100 precise protein targets. This precision science is enabling us to pioneer the discovery of innovative, highly targeted medicines that treat serious, chronic conditions safely and effectively, and help patients live better, more empowered lives.
|Range||12.160 - 12.568|
|52 Week||11.800 - 19.500|
Events & Webcasts
New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes
Cantor Fitzgerald Global Healthcare Conference
Bank of America Merrill Lynch 2017 Global Healthcare Conference
EASD 2017 Sotagliflozin Program Update
- WEBCAST: 2017 Wedbush PacGrow Healthcare Conference
Investor and Media Relations Contact
Corporate Communications and Investor Relations
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160